Send to

Choose Destination
Int J Cardiol. 2009 May 1;134(1):145-7.

Magnesium orotate in severe congestive heart failure (MACH).

Author information

Russian County Moscow University of Medicine, Moscow, Russia.

Erratum in

  • Int J Cardiol. 2009 May 1;134(1):144.

Corrected and republished in



Aim of this study was to evaluate adjuvant magnesium orotate on mortality and clinical symptoms in patients with severe heart failure under optimal cardiovascular medication.


In a monocentric, controlled, double-blind study, 79 patients with severe congestive heart failure (NYHA IV) under optimal medical cardiovascular treatment were randomised to receive either magnesium orotate (6000 mg for 1 month, 3000 mg for about 11 months, n = 40) or placebo (n = 39). Both groups were comparable in demographic data, duration of heart failure and pre- and concomitant treatment.


After mean treatment duration of 1 year (magnesium orotate: 364.1 +/- 14.7 days, placebo: 361.2 +/- 12.7 days) the survival rate was 75.7% compared to 51.6% under placebo (p < 0.05). Clinical symptoms improved in 38.5% of patients under magnesium orotate, whereas they deteriorated in 56.3% of patients under placebo (p < 0.001).


Magnesium orotate may be used as adjuvant therapy in patients on optimal treatment for severe congestive heart failure, increasing survival rate and improving clinical symptoms and patient's quality of life.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center